01—Abstract
Summary
Summary of the 10-K filed February 26, 2010. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation's 2009 10-K report reveals a company with stable net sales of $6.72 billiona, showing minimal growth year-over-year, largely due to the economic downturn impacting its MedSurg Equipment segment.
Despite this, the Orthopaedic Implants segment demonstrated resilience with a 4% increase in sales, driven by strong performance in hip, knee, trauma, and spinal implant systems. The company made a significant strategic acquisition of Ascent Healthcare Solutions for $525 millionb in cash, aiming to bolster its MedSurg segment. Stryker also managed its expenses effectively, reducing R&D spending as a percentage of sales and controlling SG&A expenses, which, combined with a patent litigation gain, helped offset some of the impacts from restructuring charges and higher cost of sales.
Investors should note the ongoing regulatory scrutiny, including FDA warning letters at several facilities, though one has been resolved. The company also highlighted its strong liquidity position and access to credit facilities to fund future operations and growth initiatives.
02—Key points
Key Highlights
- Stryker reported stable net sales of $6.72 billion for the year ended December 31, 2009, with minimal year-over-year growth.
- The Orthopaedic Implants segment showed robust performance, with net sales increasing by 4% to $4.12 billion, driven by strong demand across various implant categories.
- The MedSurg Equipment segment experienced a 5% decline in net sales to $2.60 billion, primarily attributed to the general economic slowdown impacting hospital capital budgets.
- A significant strategic move was the acquisition of Ascent Healthcare Solutions, Inc. for $525 million in an all-cash transaction, aimed at enhancing the MedSurg Equipment segment.
- Research, Development, and Engineering (R&D) expenses decreased by 9% to $336.2 million, representing 5.0% of net sales, down from 5.5% in the prior year, reflecting cost control measures and a focus on compliance initiatives.
- The company reported net earnings of $1.11 billion, a slight decrease of 4% compared to the prior year, with diluted EPS of $2.77.
- Stryker continues to navigate regulatory challenges, having received FDA warning letters for several facilities, though one was resolved. The company is cooperating with the FDA to address observations.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2009, Stryker Corp kept $0.16.
- Revenue$6.72B100.0%
- Cost of revenue−$2.18B32.5%
- Gross profit$4.54B67.5%
- Operating costs−$2.94B43.8%
- Operating income$1.59B23.7%
- Interest, other & tax−$487.0M7.2%
- Net income$1.11B16.5%
Where FY2009 revenue went
$6.72B- SG&A: $2.51B, 37% of revenue
- Cost of revenue: $2.18B, 32% of revenue
- Net income: $1.11B, 16% of revenue
- R&D: $336.0M, 5.0% of revenue
- Other operating costs: $103.0M, 1.5% of revenue
- Interest, other & tax: $487.0M, 7.2% of revenue
Kept 16% as net incomeOther operating costs $103.0M · 1.5%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2009filed February 26, 2010Financial Statements
FY2009 against FY2008
| Line item | FY2009FY2008 | Change |
|---|---|---|
| Revenue | $6.72B$6.72B | +0.1% |
| Cost of Revenue | $2.18B$2.13B | +2.5% |
| Gross Profit | $4.54B$4.59B | −1.0% |
| R&D Expenses | $336.00M$367.80M | −8.6% |
| SG&A Expenses | $2.51B$2.63B | −4.5% |
| Operating Expenses | $2.94B$3.07B | −4.0% |
| Operating Income | $1.59B$1.52B | +4.9% |
| Interest Expense | $14.00M$12.70M | +10.2% |
| Net Income | $1.11B$1.15B | −3.6% |
| EPS (Basic) | $2.79$2.81 | −0.7% |
| EPS (Diluted) | $2.77$2.78 | −0.4% |
| Shares Outstanding (Basic) | 397.40M408.10M | −2.6% |
| Shares Outstanding (Diluted) | 399.40M413.60M | −3.4% |
05—Questions
Frequently Asked Questions
How did the acquisition of Ascent Healthcare Solutions impact Stryker's financial performance in 2009?
The acquisition of Ascent Healthcare Solutions, Inc. for $525 million was completed at the end of 2009. While it significantly expanded Stryker's presence in the reprocessing and remanufacturing of medical devices, its financial impact on net sales and operating income for the year 2009 was not material as it was a partial-year acquisition. However, it is expected to enhance the MedSurg Equipment segment and provide cost savings opportunities for customers.
What were the key drivers of sales growth in the Orthopaedic Implants segment?
The Orthopaedic Implants segment saw a 4% increase in sales to $4.12 billion. This growth was primarily driven by higher shipments across various implant systems, including hips (with strong performance from Trident, X3 Polyethylene, Accolade, and Restoration Modular Hip System), knees (particularly the Triathlon Knee System), trauma (Gamma 3 Hip Fracture System, SPS Calcaneal Foot Plating System, VariAx Distal Radius System), and spinal implant systems (thoracolumbar, interbody, and cervical implants).
What challenges did Stryker face in its MedSurg Equipment segment, and how did it impact performance?
The MedSurg Equipment segment experienced a 5% decrease in net sales, reaching $2.60 billion. The primary challenge was the general economic slowdown in the United States, which led to a significant contraction in hospital capital budgets. This reduced demand for certain MedSurg products, especially capital equipment which represents about 60% of the segment's sales, to a degree not previously seen in recessionary periods.
How is Stryker managing its research and development (R&D) investments in the current economic climate?
In 2009, Stryker reduced its R&D expenditures by 9% to $336.2 million, representing 5.0% of net sales, down from 5.5% in 2008. This reduction was attributed to tight control over discretionary spending and a focused allocation of R&D resources towards compliance initiatives. Despite the decrease, the company continued to introduce new products in both its Orthopaedic Implants and MedSurg Equipment segments.
06—Continue